Pluristem Announces DMC Recommendation Following Interim Analysis of its Phase III CLI Study
December 09, 2020 04:00 ET
|
Pluristem Therapeutics, Inc.
The CLI study is unlikely to meet its primary endpoint by the time of the final analysis Substantial low number of events in the placebo group in the CLI study decreased the statistical power of the...
Pluristem to Present Initial Results from Its Phase I HCT Study with PLX-R18 Demonstrating Safety and Efficacy at the ASH Annual Meeting
November 18, 2020 07:00 ET
|
Pluristem Therapeutics, Inc.
PLX-R18 demonstrated significant clinical improvements in Hb, ANC, and PLT among the high-dose cohortPLX-R18 was found to be safe and well-toleratedTopline results from the full Phase I clinical trial...
World Experts in Infectious Diseases & Critical Care Form Pluristem’s COVID-19 Steering Committee
October 20, 2020 07:00 ET
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products,...
Pluristem Announces Clearance to Move Forward with Enrollment for Cohort II in an Investigator-Led Phase I/II Chronic Graft vs Host Disease Study
October 13, 2020 07:00 ET
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products,...
Pluristem Expands its Phase II COVID-19 European Clinical Trial to Israel
October 07, 2020 02:00 ET
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
Abu Dhabi Stem Cells Center and Pluristem Unveil Joint Projects at Malta Conferences Foundation Online Event
October 01, 2020 03:00 ET
|
Pluristem Therapeutics, Inc.
The Malta Conferences address the shared desire to improve quality of life and political stability in the Middle East through scientific collaboration HAIFA, Israel, Oct. 01, 2020 (GLOBE NEWSWIRE)...
Pluristem CEO Issues Shareholder Update
September 15, 2020 07:30 ET
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products,...
Pluristem Launches FDA-Cleared COVID-19 Expanded Access Program, Enabling Patient Treatment Outside of Clinical Trial
August 27, 2020 07:00 ET
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
Pluristem Announces End of Patient Enrollment in its Phase I Hematology Study
August 19, 2020 07:00 ET
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
Pluristem and Abu Dhabi Stem Cells Center Sign MOU to Collaborate in the Development of Cell Therapies and Regenerative Medicines for the Treatment of Severe Diseases Including COVID-19
August 17, 2020 02:00 ET
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...